News for Bicycle Therapeutics plc (BCYC)

Morgan Stanley analyst Jeffrey Hung has updated the price target for Bicycle Therapeutics (BCYC), raising it from a previous target of $15.00 to a new target of

Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on May 1, 2025, the Compensation Committee of the company's Board of Directors granted to 13 new

Morgan Stanley has adjusted its price target for Bicycle Therapeutics (BCYC), increasing it from $15 to $17. Despite maintaining an Equal Weight rating on the s

We recently published a list of Top 11 Small Cap Stocks to Buy with Biggest Upside Potential. In this article, we are going to take a look at where Bicycle Therapeutics plc (NASDAQ:BCYC) stands against other top small cap stocks to buy with biggest upside potential. On April 24, Jill Carey Hall, BofA Securities head […]

We recently published a list of Top 11 Small Cap Stocks to Buy with Biggest Upside Potential.

Barclays has revised its price target for Bicycle Therapeutics (BCYC), decreasing it from $40 to $15. Despite this adjustment, the firm maintains an Overweight

Bicycle Therapeutics (BCYC) reported first-quarter revenue of $9.98 million, surpassing the consensus estimate of $8.67 million. The company continues to make h

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic p

Revenue: $7.78 million, meeting the estimated revenue for the quarter.Earnings Per Share (EPS): -$0.86, aligning with the estimated EPS for the quarter.Cash Po

Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicycli

Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on March 3, 2025, the Compensation Committee of the company's Board of Directors granted to eight

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic p

On December 31, 2024, Deep Track Capital, LP (Trades, Portfolio) executed a significant transaction involving Bicycle Therapeutics PLC (BCYC). The firm reduced

Bicycle Therapeutics' BT8009 offers strong safety and efficacy. Find out why BCYC stock could be a buy, despite recent volatility and awaiting mid-2025 data.

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic p

Biocom California Appoints New Members to its Board of Directors

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic p

Bicycle Therapeutics CFO Alethia Young sells shares totaling $19,655

Bicycle Therapeutics CTO sells shares worth $60,119